The restricted mean survival time (RMST) analysis technique was introduced in health care research about 25 years ago and since then has become widely used in economics, engineering, business and ...

Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic headwinds. A key catalyst was last week’s announcement from rival Eli Lilly LLY, ...

If you're one of the many people who have been interested in Ozempic-style weight loss medications but are terrified of ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Weight loss drugs, already a relatively new and revolutionary concept within the medical industry, are shaking things up once again. Move over Ozempic, pharmaceutical giant Eli Lilly […] ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...